LXEO stock news · Lexeo Therapeutics
Get alerts for LXEO
Follow Lexeo Therapeutics (LXEO) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for LXEOLexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 and Q3 2026 Financial Results
Good for LXEOLexeo reported LX2020 interim results with mean reductions of 80% in NSVT and 44% in premature ventricular contractions. This favors LXEO, with cash expected to last into 2028.
Lexeo Therapeutics showed an 80% drop in heart rhythm issues in its study on genetic heart disease.
Good for LXEOLexeo reported an 80% average drop in one heart rhythm problem among 7 high-dose patients, and a 44% drop in early extra beats. The results favor Lexeo.
Lexeo Therapeutics, Inc.: Results of Operations and Financial Condition (LXEO)
Good for LXEOLexeo reported an 80% mean drop in one heart-rhythm measure and a 44% mean drop in another in high-dose groups. The early results make this update positive for Lexeo.
Lexeo Therapeutics will share its third quarter 2026 results and an update on LX2020 on November 16, 2026.
NeutralLexeo set November 16, 2026, to report third-quarter results and discuss its LX2020 trial. No results or trial findings are included, so the notice does not change its outlook.
Lexeo Therapeutics finished buying Mantle and paid with cash and company shares.
NeutralLexeo completed its purchase of Mantle using cash and shares, with more payments possible if milestones are met. The filing does not show how the deal changes Lexeo's prospects.
Lexeo Therapeutics finished buying Mantle for $8.3 million in cash and stock.
NeutralLexeo completed its purchase of Mantle for cash and shares, with more payments tied to milestones. The filing gives no results showing what Mantle adds, so the outlook is unchanged.
Lexeo Therapeutics, Inc. has signed an important agreement to merge with Mantle Therapeutics Inc.
NeutralLexeo announced a merger to acquire Mantle for $5.3M cash plus $3.0M stock; deal size and uncertain obligations leave Lexeo's standing unchanged.